The Clinical Research Unit is critical to the conduct of clinical cancer research within the Cancer Center. This Shared Resource is a centralized administrative unit that provides data management coordination, protocol coordination and centralized regulatory affairs, oncology research nurse coordination, investigational drug services and protocol management for clinical trials conducted by Cancer Center members. The Clinical Research Unit supports peer-review funded clinical research projects, cooperative clinical trials and protocols reviewed and approved by the Cancer Center's Clinical Trials Scientific Review and Monitoring Committee. By providing the necessary infrastructure for the transfer of preclinical discoveries into the clinical arena, this Shared Resource is critical to the Cancer Center's effort to stimulate translational research and to support high quality clinical trials. The availability of highly skilled data management staff, regulatory affairs expertise, oncology research nurses and pharmacists experienced in clinical trial initiation, conduct and monitoring encourages Cancer Center members to develop and conduct clinical trials involving novel agents and innovative treatment approaches. The Clinical Research Unit has been continuously funded by the Core Grant since 1981. Since 1992, Lynn Schuchter, MD, an expert in clinical trials involving experimental therapeutics and in multi-modality trials for melanoma, has served as Facility Director. Her scientific expertise, active involvement in national cooperative groups, and administrative skills has resulted in highly effective management and development of this core during the past seven years. 6522 adult patients were entered onto clinical treatment protocols this past year and 85 protocols were activated this past year. This represents a 28% increase in patient accrual and a three- fold increase in the number of studies activated in the past year.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016520-26S1
Application #
6456204
Study Section
Project Start
2000-12-01
Project End
2001-11-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
26
Fiscal Year
2001
Total Cost
$228,564
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7
Raghunathan, Nirupa Jaya; Korenstein, Deborah; Li, Qing S et al. (2018) Determinants of mobile technology use and smartphone application interest in cancer patients. Cancer Med 7:5812-5819
Hordeaux, Juliette; Wang, Qiang; Katz, Nathan et al. (2018) The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice. Mol Ther 26:664-668
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N et al. (2018) Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med 10:
Torre, Eduardo; Dueck, Hannah; Shaffer, Sydney et al. (2018) Rare Cell Detection by Single-Cell RNA Sequencing as Guided by Single-Molecule RNA FISH. Cell Syst 6:171-179.e5

Showing the most recent 10 out of 1047 publications